伴高危复发风险肝细胞癌术后辅助治疗的研究进展OA
Research progress in adjuvant therapy for hepatocellular carcinoma with a high risk of postoperative recurrence
肝细胞癌(HCC)是最常见的原发性肝癌类型,手术切除是可切除HCC患者的首选治疗方式.然而,术后高达70％的复发率是限制肝癌患者长期生存获益的关键因素,术后辅助治疗或是降低肝癌高复发率的有效治疗选择.因而,伴有高危复发风险肝癌患者的术后辅助治疗策略,近年来愈加受到重视.该文综述了目前针对HCC术后辅助治疗的系列研究,包括局部治疗和系统治疗等,以期为HCC术后高危复发风险患者制订有效的辅助治疗策略和术后辅助治疗的相关研究提供参考.
Hepatocellular carcinoma(HCC)is the most common type of primary liver cancer,and surgical resection remains the first-line treatment for patients with resectable disease.However,postoperative recurrence rates of up to 70％severely limit the long-term survival benefits of patients with HCC.Adjuvant therapy after surgery is therefore considered a potential effective strategy to reduce the high risk of recurrence.Accordingly,postoperative adjuvant treatment strategies for patients with HCC at high risk of recurrence have attracted increasing attention in recent years.This review summarizes current studies on adjuvant therapies following curative resection for HCC,including both locoregional and systemic treatments,with the aim of providing a reference for the development of effective adjuvant treatment strategies and future research in patients with a high risk of postoperative recurrence.
马金尼;李梓豪;刘福晨;朱秀丽
安徽医科大学第一临床医学院,安徽 合肥 230032安徽医科大学第一临床医学院,安徽 合肥 230032中国人民解放军海军军医大学第三附属医院(上海东方肝胆外科医院)肝外三科,上海 200438中国科学技术大学附属第一医院(安徽省立医院)消化内科,安徽 合肥 230001
医药卫生
肝细胞癌肝切除术辅助治疗复发转移
hepatocellular carcinomahepatectomyadjuvant therapyrecurrence and metastasis
《中国现代医学杂志》 2026 (6)
29-33,5
国家自然科学基金青年项目(No:82302906)
评论